Invention Grant
- Patent Title: Sustained-release dosage forms of ruxolitinib
-
Application No.: US17847734Application Date: 2022-06-23
-
Publication No.: US11576864B2Publication Date: 2023-02-14
- Inventor: Yong Ni , Bhavnish Parikh , Krishnaswamy Yeleswaram , Susan Erickson-Viitanen , William V. Williams
- Applicant: Incyte Corporation , Incyte Holdings Corporation
- Applicant Address: US DE Wilmington; US DE Wilmington
- Assignee: Incyte Corporation,Incyte Holdings Corporation
- Current Assignee: Incyte Corporation,Incyte Holdings Corporation
- Current Assignee Address: US DE Wilmington; US DE Wilmington
- Agency: Fish & Richardson P.C.
- Main IPC: A61K9/20
- IPC: A61K9/20 ; A61K31/519
Abstract:
The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
Public/Granted literature
- US20220323363A1 SUSTAINED-RELEASE DOSAGE FORMS OF RUXOLITINIB Public/Granted day:2022-10-13
Information query
